- Home
- HROW vs BCSF Comparison
HROW vs BCSF Comparison
Compare HROW & BCSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HROW
- BCSF
- Stock Information
- Founded
- HROW 1998
- BCSF 2015
- Country
- HROW United States
- BCSF United States
- Employees
- HROW N/A
- BCSF N/A
- Industry
- HROW Biotechnology: Pharmaceutical Preparations
- BCSF Finance/Investors Services
- Sector
- HROW Health Care
- BCSF Finance
- Exchange
- HROW Nasdaq
- BCSF Nasdaq
- Market Cap
- HROW 1.1B
- BCSF 1.0B
- IPO Year
- HROW N/A
- BCSF 2018
- Fundamental
- Price
- HROW $30.66
- BCSF $14.92
- Analyst Decision
- HROW Strong Buy
- BCSF Buy
- Analyst Count
- HROW 6
- BCSF 2
- Target Price
- HROW $59.00
- BCSF $16.50
- AVG Volume (30 Days)
- HROW 433.0K
- BCSF 206.0K
- Earning Date
- HROW 08-06-2025
- BCSF 08-05-2025
- Dividend Yield
- HROW N/A
- BCSF 0.80%
- EPS Growth
- HROW N/A
- BCSF N/A
- EPS
- HROW N/A
- BCSF 1.75
- Revenue
- HROW $212,858,000.00
- BCSF $284,993,000.00
- Revenue This Year
- HROW $44.92
- BCSF N/A
- Revenue Next Year
- HROW $38.12
- BCSF N/A
- P/E Ratio
- HROW N/A
- BCSF $8.54
- Revenue Growth
- HROW 53.49
- BCSF N/A
- 52 Week Low
- HROW $19.31
- BCSF $13.20
- 52 Week High
- HROW $59.23
- BCSF $19.21
- Technical
- Relative Strength Index (RSI)
- HROW 57.58
- BCSF 38.84
- Support Level
- HROW $30.01
- BCSF $14.69
- Resistance Level
- HROW $31.63
- BCSF $15.09
- Average True Range (ATR)
- HROW 1.59
- BCSF 0.24
- MACD
- HROW 0.02
- BCSF -0.09
- Stochastic Oscillator
- HROW 66.10
- BCSF 17.56
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
About BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing predominantly in middle-market companies with between $10.0 million and $150.0 million in annual EBITDA. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan among others.